Vela Technologies #VELA – Quarterly Investment Update November 28, 2024 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an investment update for the quarter ended 30 September 2024. Key numbers as at 30 September 2024 · The value of Vela’s total assets (including cash) increased by £251,000 during the quarter to £3,055,000 from £2,804,000 (quarter to 30 June 2024 – a decrease of £2,737,000). · The fair value of the investment portfolio (excluding cash)…

Vela Technologies #VELA – Update re. investment in Conduit Pharmaceuticals Inc. August 9, 2024 – Posted in: Vela Technologies Plc (VELA)

The Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, notes the announcement released by Conduit Pharmaceuticals Inc. (“Conduit”) on 8 August 2024 regarding Conduit entering into an exclusive licence agreement with AstraZeneca for multiple assets to advance potential first-in-class treatments. Vela holds 1,005,760 common shares in Conduit representing 0.46% of Conduit’s issued share capital. At the closing mid-market price of $0.17 on 8 August 2024,…

Vela Technologies #VELA investee co Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 8, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee company Conduit Pharmaceuticals has entered into an agreement with AstraZeneca Plc (NASDAQ:AZN) to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase activators and AZD5904, a myeloperoxidase inhibitor (MPO). AstraZeneca had progressed AZD1656 and AZD5904 through Phase 1 clinical trials. Conduit initially intends to conduct Phase 2 clinical trials on candidates AZD1656 and AZD5658 in 2024 for applications in autoimmune disorders. Under the terms of the License Agreement,…

Vela Technologies #VELA – Investee co Conduit Pharmaceuticals secures $2.65 million funding – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA is pleased to note that investee pharmaceutical co Conduit Pharmaceuticals Inc. (NASDAQ:CDT) has entered into a financing agreement securing $2.65 million through a Senior Secured Promissory Note with Nirland Limited. The agreement, effective Monday, includes an issuance of 12.5 million shares of common stock to the purchaser. The promissory note carries an annual interest rate of 12%, accruing daily, with the option for the purchaser to receive interest payments in cash or…

Vela Technologies #VELA – Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases July 17, 2024 – Posted in: Vela Technologies Plc (VELA)

Read here Conduit Pharmaceuticals Inc. (Nasdaq: CDT) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator which targets a wide range of autoimmune diseases. The Company is enrolled to participate in the Patent Prosecution Highway (PPH), a program to fast-track patent examination in major jurisdictions including the U.S., Europe and Japan. Since IP Australia has allowed…

Vela Technologies #VELA – Quarterly Investment Update February 23, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 31 December 2023. Key numbers as at 31 December 2023* · The value of Vela’s total assets (including cash) decreased during the quarter by £639,000 (9%) to £6,180,000 (quarter to 30 September 2023 – increase of £942,000 to £6,819,000 (16%)). · Vela’s portfolio comprised a total of 15…

Vela Technologies #VELA – Update re. investment in Conduit Pharmaceuticals Inc. August 9, 2024 – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA investee co Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 8, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies #VELA – Investee co Conduit Pharmaceuticals secures $2.65 million funding – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA – Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases July 17, 2024 – Posted in: Vela Technologies Plc (VELA)

Vela Technologies #VELA – Quarterly Investment Update February 23, 2024 – Posted in: Blog, Vela Technologies Plc (VELA)

Address

Contact

Social

LEGAL